Compare RKDA & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RKDA | CDIO |
|---|---|---|
| Founded | 2002 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8M | 5.3M |
| IPO Year | 2015 | N/A |
| Metric | RKDA | CDIO |
|---|---|---|
| Price | $3.68 | $2.93 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 16.4K | ★ 30.7K |
| Earning Date | 11-07-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,173,000.00 | $15,782.00 |
| Revenue This Year | $21.31 | $1,434.82 |
| Revenue Next Year | $28.33 | $4,661.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.31 | N/A |
| 52 Week Low | $2.53 | $2.42 |
| 52 Week High | $10.31 | $53.10 |
| Indicator | RKDA | CDIO |
|---|---|---|
| Relative Strength Index (RSI) | 47.28 | 44.61 |
| Support Level | $3.48 | $2.85 |
| Resistance Level | $3.76 | $3.13 |
| Average True Range (ATR) | 0.18 | 0.32 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 43.09 | 59.45 |
Arcadia Biosciences Inc is a producer and marketer of plant-based food and beverage products. It is engaged in science-based approaches to developing high-value crop improvements in wheat, soy, and hemp, designed to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health, and wellness products, and their viability for industrial applications. The company's consumer brands in the food, beverage, and body care categories include GoodWheat high-fiber pasta, Zola coconut water, and others.
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.